Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Dunbar

Showing results (331-340 of 332) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 332 results.
Cancer Discovery|January 17, 2024
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew J Dunbar, Robert L Bowman, Young C Park, et al.
Blood Advances|October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AMLSheng F Cai, Ying Huang, Jennie R Lance, et al.
Pageof 34

Showing results (331-340 of 332) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 332 results.
Cancer Discovery|January 17, 2024
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew J Dunbar, Robert L Bowman, Young C Park, et al.
Blood Advances|October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AMLSheng F Cai, Ying Huang, Jennie R Lance, et al.
Pageof 34